Mizuho analyst Ann Hynes downgraded Select Medical (SEM) to Neutral from Outperform with a price target of $16.50, down from $17. The company is being taken private with the deal expected to close in mid-2026, pending shareholder approval, the analyst tells investors in a research note. Mizuho views the $16.50 in cash per share price as fair.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SEM:
- Proposed Merger Poses Operational and Valuation Risks for Select Medical
- Select Medical Balances Growth, Margin Strain in Earnings Call
- Select Medical Declares Dividend Amid Mixed Quarterly Results
- Select Medical reports Q1 adjusted EPS 36c, consensus 46c
- Select Medical reaffirms FY26 adjusted EPS view $1.22-$1.32, consensus $1.26